Galmed Pharma

GLMD NASDAQ
6.24
-0.17
-2.65%
Pre Market: 6.40 +0.16 +2.56% 07:51 07/22 EDT
Open
6.30
Prev Close
6.41
High
6.42
Low
6.23
Volume
36.58K
Avg Vol (3M)
62.86K
52 Week High
15.60
52 Week Low
5.48
% Turnover
0.17%
Market Cap
131.75M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Galmed Pharma GLMD stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
MORE >

Recently

Name
Price
%Change